
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

DeFi Technologies Subsidiary Valour launches Asset-backed Ethereum Physical Staking ETP for Professional Investors on the London Stock Exchange




